American Oriental Bioengineering (广西博科药业) found itself, once again, defending one of management’s initiatives. Last week, AOB said it had closed a $70 million purchase of buildings and land in Beijing. Unfortunately for AOB, the release said the site and its facilities would be used as a “Convention and Training Center.” Critics jumped all over the wording, charging that AOB was abandoning its very profitable and growing drug business in order to begin holding conventions. More details...

Stock Symbol: (NYSE: AOB)